5 June 2026

Comparing Major Adverse Kidney Events (MAKE) Among New Users of Oral Semaglutide (SEMA) Versus Select Oral Antidiabetic Medications (ADMs) Among US Adults With Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress poster

GLP-1 RA

Semaglutide (oral)

RWE HEOR

Are you a healthcare professional?